Hanmi

BH3120 is a heterodimeric bispecific antibody (PENTAMBODY) designed to target 4-1BB and PD-L1 simultaneously to stimulate anti-tumor immune response either by inhibition of an immune checkpoint mechanism and by activation of a co-stimulatory signal in tumor microenvironment (TME) focused manner.

Non-clinical observations with BH3120, either as a monotherapy or in combination settings, consistently explain strong anti-tumor T cell activities in tumor tissue specific manner with clear dose dependency, while systemic immune response is minimally modulated.

These properties support further evaluation of the immune-modulating bispecific antibody, and BH3120 will be studied as a therapeutic candidate with multiple types of solid tumors.

• Inhibition of PD-1/PD-L1, T cell- co-stimulatory signaling by 4-1BB agonism
• Conditional, PD-L1 binding dependent, 4-1BB activation in tumor tissue specific manner
• Well balanced efficacy and safety in mono and combination settings

BH3120, a bispecific antibody targeting 4-1BB and PD-L1 simultaneously, stimulates T cells in tumor tissue preferred manner

Poster, American Association for Cancer Research (AACR) 114th Annual meeting, 2023

BH3120: A novel bispecific antibody targeting 4-1BB and PD-L1 with well balanced efficacy and safety profiles

Poster, American Association for Cancer Research (AACR) 113th Annual meeting, 2022

Jan 19, 2021

Hanmi Pharmaceutical expects U.S. FDA approval for 2 new drugs

Jan 16, 2020

[38th J.P. Morgan Healthcare Conference] Hanmi, ready to lead global pharmaceutical market with innovative R&D pipeline

Jan 15, 2018

Hanmi seeks global expansion with innovative drugs for NASH, rare diseases and targeted anti-cancer drugs